EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Maternal Resistance to Thyroid Hormone β and Pregnancy Outcomes

Carla Moran, Krishna Chatterjee iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad350 ↗

Kurz gefasst

Editorial in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Carla Moran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Section, Beacon Hospital, Dublin, D18 AK68, Ireland. Hauptthemen laut MEDLINE: Pregnancy Outcome, Thyroid Hormones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Wellcome, National Institute for Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to thyroid hormone β (RTHβ), a dominantly inherited disorder, typically due to heterozygous mutations (over 230 different mutations described hitherto) in the thyroid hormone β receptor (TRβ), which mediates negative feedback by thyroid hormones (THs) within the hypothalamo–pituitary–thyroid axis, is characterized by raised circulating TH (free thyroxine [T4] and free triiodothyronine [T3]) and nonsuppressed thyrotropin [TSH]. The clinical phenotype of RTHβ is variable, encompassing both hyperthyroid (eg, failure to thrive in infancy; anxiety, tachycardia, low body weight in adults) and hypothyroid (eg, dyslipidemia, steatosis) features, attributable to the actions of elevated TH on either hormone-sensitive, TRα-expressing tissues or hormone-resistant, TRβ-expressing organs, respectively (1). Knowledge that conventional maternal hyperthyroidism (eg, due to Graves' disease) has deleterious consequences in pregnancy prompts consideration of what the outcomes of pregnancies in which a hyperthyroxinemic mother with RTHβ carries a fetus of either concordant (TRβ mutant) or discordant (wild-type or normal TRβ) genotype might be. A landmark study, in a large RTHβ kindred within the Azores, showed that the risk of miscarriage (22%) was increased in affected mothers with this condition (2). In addition, unaffected infants born to affected RTHβ mothers, were significantly smaller for gestational age (SGA) than affected infants and also had undetectable TSH levels at birth. While the unique geographic location of this RTHβ cohort enabled the authors to control for other variables that could have confounded their findings, it is noteworthy that, in this population, the disorder is caused by a single (Arg243Gln) TRβ mutation. Nevertheless, a subsequent study (3) in the same RTHβ population showed that unaffected offspring of RTHβ mothers exhibit resistance to TH within the pituitary–thyroid axis, providing further evidence of maternal hyperthyroxinemia affecting offspring outcomes. Indeed, the authors documented the same phenomenon in normal offspring of TRβ mutant mice and suggested that increased expression of type 3 deiodinase (D3), an enzyme that inactivates both T4 and T3, seen in anterior pituitary of offspring animals, might account for such axis resistance (3). Although a later study from Israel, comprising 11 pregnancies in a genetically heterogeneous RTHβ patient cohort, has documented complications (miscarriages, SGA infants), these morbidities were not overrepresented in unaffected children of TRβ mutation–carrying mothers (4). Other reports of single or small case series of pregnancies in RTHβ mothers have reported benign outcomes (5). Possible explanations for this discrepancy are the genetic heterogeneity of RTHβ in non-Azorean populations, with different TRβ mutations being associated with varying degrees of maternal hyperthyroxinemia, affecting pregnancy outcomes differently; or the inability to control for other variables or power studies with enough pregnancies in non-Azorean contexts has confounded or limited their results. A report of antenatal genetic testing (via amniocentesis at 3 months) showing an unaffected fetus, prompted propylthiouracil treatment of a pregnant RTHβ patient (with Arg317Thr mutant TRβ), with delivery of a normal birthweight (3.1 kg) infant and normal cord blood TH and TSH (6). This case outlined a possible approach to the management of maternal RTHβ in pregnancy, combining prenatal genotyping to identify unaffected fetuses with antithyroid drug treatment to limit maternal TH levels for the remainder of gestation (6). A subsequent study sought to validate this approach, identifying unaffected fetuses (by amniocentesis or chorionic villus sampling) in RTHβ pregnancies of differing mutant TRβ genotype, and intervening with antithyroid drug treatment in a subset of them, documenting no difference in birth weight or neonatal TSH levels between unaffected or RTHβ offspring (7). The authors acknowledged that prenatal testing would not have avoided miscarriage of unaffected fetuses and also that their study was not a controlled trial comparing outcomes with a nonintervention group. Although undoubtedly feasible, this approach cannot be followed fully if, for instance, an RTHβ patient declines prenatal genetic testing (5). It has also been suggested that unless maternal free T4 exceeds 150% of the upper limit of normal as pregnancy progresses, prenatal genetic diagnosis and intervention with antithyroid drug treatment might be safely avoided (7). On this background, the recent study by Salas-Lucia and colleagues (8) provides important new knowledge. Here, the authors studied placental gene expression in 2 pregnancies of the same patient with RTHβ (Gly307Asp TRβ mutation), 1 carrying a normal (male) fetus and the other an affected (female) fetus. Importantly, in the pregnancy with an unaffected fetus, placental D3 and type 2 deiodinase (D2) enzyme activities were maintained or slightly increased, with upregulation of their corresponding mRNAs, implying fetal protection from exposure to high maternal TH levels. Conversely, in the pregnancy with an affected fetus, placental D3 and D2 activity was reduced; although this could increase placental TH content, a concomitant observed reduction in placental expression of TH transporters makes the net effect on transplacental passage of TH hard to predict. Overall, these studies suggest that a prospective study of RTHβ pregnancies to determine outcomes is both feasible and warranted. With nearly 1000 RTHβ families known worldwide (1), it should be possible to enroll participants with a diverse repertoire of TRβ mutations, likely associated with a wide range of elevated circulating TH, which can be recorded prepregnancy and then in each trimester. A multicenter study, from different geographic locations, would ensure fair representation of participants of differing ethnic background and socioeconomic status. Outcomes recorded at birth would include the timing and mode of delivery, birth weight, neonatal TH and TSH, and TRβ genotype. As shown by Salas and colleagues, the expression of placental enzymes and transporters governing transplacental passage of TH can be measured to determine, for instance, whether unaffected fetuses are protected from exposure to even higher maternal TH levels; as placental D3 activity differs with fetal THRB genotype (8) and this gene is known to be imprinted (3) it may be possible to investigate underlying epigenetic mechanisms in placental tissue. Most importantly the results of a prospective study could better inform whether, when, and how intervention to alter maternal TH levels in an RTHβ pregnancy, is warranted. Our research is supported by Wellcome (210755/Z/18/Z) and the National Institute for Health Research Cambridge Biomedical Research Centre. The authors have nothing to disclose. type 2 deiodinase type 3 deiodinase resistance to thyroid hormone β smaller for gestational age triiodothyronine thyroxine thyroid hormone thyroid hormone β receptor thyrotropin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnancy OutcomeThyroid HormonesPregnancyFemaleHumansPlacentaFetus

Stichwörter der Autor:innen

pregnancyresistance to thyroid hormone betatransplacental passage of thyroid hormones

Substanzen

Thyroid Hormones

Autor:innen und Institutionen

  • Endocrine Section, Beacon Hospital, Dublin, D18 AK68, Ireland.
  • Department of Endocrinology, St Vincent's University Hospital, Dublin, D04 T6F4, Ireland.
  • School of Medicine, University College Dublin, Dublin, D04 C7X2, Ireland.
  • Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK.

ORCID-Profile: Krishna Chatterjee

Förderung

  • Wellcome Trust
  • Wellcome
  • National Institute for Health Research

Zitieren

APA

Moran, C., & Chatterjee, K. (2023). Maternal Resistance to Thyroid Hormone β and Pregnancy Outcomes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad350

Vancouver

Moran C, Chatterjee K. Maternal Resistance to Thyroid Hormone β and Pregnancy Outcomes. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad350

BibTeX
@article{Moran2023,
  author = {Moran, Carla and Chatterjee, Krishna},
  title = {Maternal Resistance to Thyroid Hormone β and Pregnancy Outcomes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad350}
}
Kostenlos starten →